DJI46,558.47-0.26%
GDAXI23,447.29-0.60%
GSPC6,632.19-0.61%
HSI25,465.60-0.98%
IXIC22,105.36-0.93%
N22553,819.61-1.16%
AAPL250.12-2.21%
AMZN207.67-0.89%
CL98.71+3.11%
EURUSD1.1423-0.82%
GBPUSD1.3223-0.93%
GC5,061.70-1.25%
GOOG301.46-0.58%
JPM283.44+0.19%
META613.71-3.83%
MSFT395.55-1.58%
NVDA180.25-1.59%
TSLA391.20-0.96%
DJI46,558.47-0.26%
GDAXI23,447.29-0.60%
GSPC6,632.19-0.61%
HSI25,465.60-0.98%
IXIC22,105.36-0.93%
N22553,819.61-1.16%
AAPL250.12-2.21%
AMZN207.67-0.89%
CL98.71+3.11%
EURUSD1.1423-0.82%
GBPUSD1.3223-0.93%
GC5,061.70-1.25%
GOOG301.46-0.58%
JPM283.44+0.19%
META613.71-3.83%
MSFT395.55-1.58%
NVDA180.25-1.59%
TSLA391.20-0.96%
DJI46,558.47-0.26%
GDAXI23,447.29-0.60%
GSPC6,632.19-0.61%
HSI25,465.60-0.98%
IXIC22,105.36-0.93%
N22553,819.61-1.16%
AAPL250.12-2.21%
AMZN207.67-0.89%
CL98.71+3.11%
EURUSD1.1423-0.82%
GBPUSD1.3223-0.93%
GC5,061.70-1.25%
GOOG301.46-0.58%
JPM283.44+0.19%
META613.71-3.83%
MSFT395.55-1.58%
NVDA180.25-1.59%
TSLA391.20-0.96%
CYBERETIKAGLOBAL FINANCIAL INTELLIGENCE
LIVE
USA Yahoo Finance EN

AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn’s Disease

Mar 09, 2026 &03460909202631; 08:46 UTC finance.yahoo.com Trending 3/5
Read original on finance.yahoo.com ↗
↗
Positive for markets
Sentiment score: +75/100
High impact Medium-term (weeks)
WHAT THIS MEANS
AbbVie announced positive Phase 3 AFFIRM study results for SKYRIZI subcutaneous induction in Crohn's disease patients, demonstrating efficacy and supporting potential label expansion. This represents a significant clinical validation that could drive revenue growth and strengthen AbbVie's gastroenterology portfolio.
AI CONFIDENCE
85% Very high
SENTIMENT GAUGE
NEWS POWER SCORE
AFFECTED ASSETS
↑
ABBV
ABBVStock
Expected to rise
Positive Phase 3 clinical trial results for SKYRIZI expansion into Crohn's disease market, supporting future revenue growth and potential FDA approval
↑
S&P 500
^GSPCIndex
Expected to rise
Positive healthcare/pharma news provides modest support to broader market sentiment
PRICE HISTORY
Loading chart...
⚡ SUGGESTED ACTION
Consider accumulating ABBV on any near-term weakness as positive Phase 3 data supports medium-term upside. Monitor FDA approval timeline and competitive landscape in Crohn's disease treatment market for confirmation of commercial potential.
KEY SIGNALS
Positive Phase 3 clinical trial dataLabel expansion opportunity for SKYRIZICrohn's disease market penetrationPotential FDA approval catalystRevenue diversification in gastroenterology
SECTORS INVOLVED
HealthcarePharmaceuticalsBiotechnology
Analysis generated on Mar 09, 2026 at 14:22 UTC
Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Yahoo Finance. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

RELATED INTELLIGENCE

AbbVie’s Skyrizi beaten by UCB’s Bimzelx in psoriatic arthritis
Seeking Alpha Mar 11, 12:31 Negative
AbbVie sees promising early-stage data for weight loss asset ABBV-295
Seeking Alpha Mar 09, 13:26 Positive
FDA plans to relax testing rules to encourage biosimilar drugs: report
Seeking Alpha Mar 09, 10:44 Positive
BMW:s vinst högre än väntat
Dagens Industri Mar 12, 06:47 Positive
NOG prices $200M equity offering at $27.75 per share
Seeking Alpha Mar 12, 06:35 Negative